added plans to structure the lit review

claude_rewrite
will king 2 years ago
parent 89d9fc0d2e
commit d6d67ad55e

@ -3,6 +3,56 @@
\begin{document}
% TODO:
%Need to distinguish that this isn't about drug development specifically, but
% more around clinical trials progress.
% Thoughts:
% - What types of failures do clinical trials have an why do clinical trials fail?
% - What is cited in termination reasons?
% - Discussion on different types of failures:
% 1. Failure to find safe and effective drug
% 2. Failure to collect enough information to determine 1
% - recruiting
% - New information (other studies, changes in standards of care, etc)
% 3. Failure due to other operational/strategic concern.
% - Issues with PI/Sponsors
% - profitability expectations
% - Financial support
% Trials can fail due to issues in one of four categories
% - Scientific: The compound-indication combo is not sufficiently safe or efficatious
% - Strategic: The result from the trial won't meet the company's strategic needs. Profitability for the most part or entry into a drug category they don't want to invest in.
% - Operational: They can't bring resources to bear to achieve goal, e.g. site planning, PI's, delivering enough financial support, etc.
% - Tactical: The plans to discover if the approach is scientifically valid are insufficient. Study design, enrollment strategies, etc.
% The literature examines many different aspects of these.
% strategic influences: elasticicity of innovation, demand pull, patents, etc
% Strategic vs scientific khmelniskaya, hwang.
% operational: Adam George Interview
% tactical: enrollment prediction.
% - Discuss how most studies are about clinical trials as part of the drug development pipeline.
% - Review what we know about causes for failure.
% - Things that correlate with failures. (adams)
% - Causes for failure (khmelnitskaya & hwang)
% - Then talk about studies on clinical trials themselves.
% - Interview with Adam George
% - Poor studies of enrollment prediction.
% -
% - Then talk about what drives approvals/clinical trial activity for drugs
% - Elasticity of innovation
% - No demand pull for novel drugs, but yes for derivatives
% - Population and Market size interact & drive development (jointly determined)
% - This doesn't apply to single trials though
% -
% - Sumarize
% - Thus when trying to study what affects clinical trials we must separate
% - Market & competition effects
% - Population effects
% - Multiple trial failure modes (safety & efficacy, Operational etc)
% -
% -
This paper sits within an intersection of health and industrial organization economics
that is frequently studied.
Encouraging a strong supply of novel and generic pharmaceuticals contributes
@ -19,7 +69,7 @@ which pharmaceutical companies operate.
% - What causes high costs of drugs?
% - High level synthesis of discussion regarding causes
% - Academic and non-academic sources
% Not particularly applicable
%%%%%%%%%%%%%%%% What do we know about clinical trials?
@ -63,7 +113,7 @@ higher if those strategic terminatations were elimintated
% Waring, Arrosmith, Leach, et al (2015)
% - Atrition of drug candidates from four major pharma companies
% - Looked at how phisicochemical properties affected clinical failure due to safety issues
%not in this version
% not Applicable in this version
@ -73,6 +123,7 @@ higher if those strategic terminatations were elimintated
% Dranov, Garthwaite, and Hermosilla (2022)
% - does the demand-pull theory of R&D explain novel compound development?
% - no, it is biased towards follow-on drug R&D.
% TODO
% Acemoglu and Linn
% - Market size in innovation
@ -89,7 +140,10 @@ Among non-generics, a 1\% increase in potential market size
% Gupta
% - Inperfect intellectual property rights in the pharmaceutical industry
%\cite{GupaPhd2023}
\cite{gupta_OneProduct_2020} discovered that uncertainty around which patents
might apply to a novel drug causes a delay in the entry of generics after
the primary patent has expired.
She found that this delay averages around 3 years.
% Agarwal and Gaule 2022
% - Retrospective on impact from COVID-19 pandemic

Loading…
Cancel
Save